Kurt Bodily, MD
Gastroenterology · Provo, UTNPI 1780600312
Payments from drug & device makers
Across 584 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Takeda Pharmaceuticals U.S.A., Inc.$968
- Johnson & Johnson$704
- Pfizer$697
- Gilead$306
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$287
- plus $3K from 31 others
What the payments were for
- Food & beverage$9,31299%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 235 | $3,814 |
| Takeda Pharmaceuticals U.S.A., Inc. | 60 | $968 |
| Johnson & Johnson | 44 | $704 |
| Pfizer | 57 | $697 |
| Gilead | 16 | $306 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $287 |
| QOL Medical, LLC | 13 | $277 |
| Merck | 17 | $263 |
| Intercept Pharmaceuticals, Inc. | 14 | $228 |
| Organon | 15 | $167 |
| Daiichi Sankyo Inc. | 10 | $164 |
| Nestle Healthcare Nutrition Inc. | 7 | $142 |
| Aimmune Therapeutics, Inc. | 9 | $140 |
| Bristol Myers Squibb | 8 | $127 |
| Regeneron Healthcare Solutions, Inc. | 8 | $126 |
| Sanofi | 7 | $122 |
| Celltrion USA Inc. | 5 | $104 |
| Endo Pharmaceuticals Inc. | 5 | $76 |
| Madrigal Pharmaceuticals | 3 | $73 |
| Ardelyx, Inc. | 2 | $70 |
| UCB, Inc. | 3 | $56 |
| Braintree Laboratories, Inc. | 2 | $52 |
| Romark Laboratories, LC | 2 | $51 |
| Acacia Pharma Inc | 6 | $48 |
| Phathom Pharmaceuticals, Inc. | 3 | $40 |
| Fresenius Kabi USA, LLC | 2 | $38 |
| Shionogi Inc | 2 | $33 |
| Dynavax Technologies Corporation | 2 | $32 |
| Boehringer Ingelheim | 1 | $27 |
| Ironwood Pharmaceuticals, Inc | 2 | $25 |
| Redhill Biopharma Inc. | 1 | $22 |
| Mylan Institutional Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $19 |
| Sandoz | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
How this compares
$9,379 in reported general payments places this provider in the 75th percentile of 122 gastroenterology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 14 | $379,144 |
| Humira(Cf) PenAdalimumab | 18 | $171,879 |
| RinvoqUpadacitinib | 14 | $159,128 |
| Mesalamine | 48 | $21,187 |
| LinzessLinaclotide | 37 | $19,369 |
| Balsalazide Disodium | 51 | $8,811 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 49 | $7,831 |
| Omeprazole | 371 | $5,537 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 201 | $4,148 |
| Famotidine | 105 | $3,524 |
| Esomeprazole Magnesium | 62 | $2,948 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 18 | $2,241 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 11 | $1,787 |
| CholestyramineCholestyramine (With Sugar) | 20 | $1,441 |
| Sucralfate | 49 | $1,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $704 | $379,14414 claims |
| AbbVieRinvoq, Linzess | $3,814 | $178,49651 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $52 | $10,07267 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $15 | $1,78711 claims |
| SandozLansoprazole | $15 | $75723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 122 gastroenterology providers in Utah.
Other gastroenterology in Provo
- Clarke HilbigProvo$29K
- Chad KawaProvo$22K
- Brett ThorpeProvo$12K
- Bryce HaslemProvo$6K
- Brandon DickinsonProvo$6K
- Thomas DickinsonProvo$4K
- John LoweOgden$3.6M
- Chad GonzalesOgden$2.9M
- John ValentineSalt Lake City$2.2M
- James TrotterMurray$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.